Immunitybio Stock Analysis

IBRX -  USA Stock  

USD 5.55  0.16  2.80%

The current slide in stock price may raise some interest from investors. The stock closed today at a share price of 5.55 on 1,699,966 in trading volume. The company directors and management have failed to build on market volatilities in December. However, diversifying your overall positions with Immunitybio may protect your principal portfolio during upcoming market swings. The stock standard deviation of daily returns for 90 days investing horizon is currently 6.71. The very high volatility is mostly attributed to the latest market swings and not very good earnings reports from some of the Immunitybio partners.
Please see Risk vs Return Analysis.

Immunitybio Stock Analysis 

 
Refresh
The Immunitybio stock analysis report makes it easy to digest most publicly released information about Immunitybio and get updates on important government artifacts, including earning estimates, SEC corporate filings, and announcements. Immunitybio Stock analysis module also helps to analyze the Immunitybio price relationship with some important fundamental indicators such as market cap and management efficiency.

Immunitybio Stock Analysis Notes

About 80.0% of the company shares are held by company insiders. The company recorded a loss per share of 0.67. Immunitybio had not issued any dividends in recent years. ImmunityBio, Inc., a clinical-stage immunotherapy company, develops cell and immune therapies to treat cancers and infectious diseases. The company was founded in 2014 and is based in San Diego, California. Immunitybio operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 538 people. To learn more about Immunitybio call the company at 858 633 0300 or check out https://immunitybio.com.

Immunitybio Investment Alerts

Many investors view ongoing market volatility as an opportunity to purchase more stocks at a favorable price or short it to generate a bearish trend profit opportunity. If you are one of those investors, make sure you clearly understand the position you are entering. Immunitybio's investment alerts are automatically generated signals that are significant enough to either complement your investing judgment regarding Immunitybio or challenge it. These alerts can help you understand what you are buying and avoid costly mistakes.
Immunitybio generated a negative expected return over the last 90 days
Immunitybio has high historical volatility and very poor performance
Immunitybio was previously known as NantKwest and was traded on NMS Exchange under the symbol NK.
The company reported the previous year's revenue of 1.49 M. Net Loss for the year was (230.49 M) with profit before overhead, payroll, taxes, and interest of 1.7 M.
Immunitybio currently holds about 80.37 M in cash with (185.79 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 0.2.
Immunitybio has a poor financial position based on the latest SEC disclosures
Roughly 80.0% of the company shares are held by company insiders
Latest headline from finance.yahoo.com: ImmunityBio Announces Results of Phase 2 Metastatic Pancreatic Cancer Trial at ASCO GI With Median Overall Survival of 6.3 Months in Patients With Third-Line Disease, More Than Doubling Historical Survival - Yahoo Finance

Immunitybio Upcoming and Recent Events

Earnings reports are used by Immunitybio to provide an update of all three financial statements, including the income statement, the balance sheet, and the cash flow statement. Every quarterly earnings report provides investors with three things: an overview of sales, expenses, and net income for the most recent period. It also may provide a comparison to Immunitybio previous reporting period. The quarterly earnings reports are usually disseminated to the public via Form 10-Q, which is a legal document filed with the Securities and Exchange Commission every quarter.
Upcoming Quarterly Report30th of December 2021
Next Fiscal Quarter End30th of September 2021
Last Quarter Report30th of June 2021
Last Earning Announcement30th of September 2020

Immunitybio Largest EPS Surprises

Earnings surprises can significantly impact Immunitybio's stock price both in the short term and over time. Negative earnings surprises usually result in a price decline. However, it has been seen that positive earnings surprises lead to an immediate rise in a stock's price and a gradual increase over time. This is why we often hear news about some companies beating earning projections. Financial analysts spend a large amount of time predicting earnings per share (EPS) along with other important future indicators. Many analysts use forecasting models, management guidance, and additional fundamental information to derive an EPS estimate.
Reported
Fiscal Date
Estimated EPS
Reported EPS
Surprise
2021-11-12
2021-09-30-0.2-0.22-0.0210 
2020-11-09
2020-09-30-0.18-0.2-0.0211 
2020-05-11
2020-03-31-0.17-0.19-0.0211 
View All Earnings Estimates

Immunitybio SEC Filings

SEC filings are important regulatory documents required of all public companies to provide to potential investors. Immunitybio prospectus issued under the guidelines of SEC is a legal declaration of facts and statements to ensure that Immunitybio investors are not misled. SEC filings are required by law to meet strict transparency standards and other important legal constraints. Although many companies may choose careful wording to disguise some material information, SEC filings make crucial Immunitybio specific information freely available to individual and institutional investors to make a timely investment decision.
12th of January 2022
Financial Statements and Exhibits. Regulation FD Disclosure. Entry into a Material Definitive Agreement
View
20th of December 2021
Financial Statements and Exhibits. Regulation FD Disclosure. Amendments to Articles of Incorporation or Bylaws; and/or Change in Fiscal Year. Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant. Entry into a Material Definitive Agreement
View
27th of September 2021
Entry into a Material Definitive Agreement
View
13th of September 2021
Financial Statements and Exhibits. Other Events. Results of Operations and Financial Condition
View
13th of August 2021
Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers
View
15th of June 2021
Financial Statements and Exhibits. Other Events. Submission of Matters to a Vote of Security Holders
View
11th of June 2021
Submission of Matters to a Vote of Security Holders. Results of Operations and Financial Condition
View
4th of June 2021
Financial Statements and Exhibits. Regulation FD Disclosure
View

Immunitybio Market Capitalization

The company currently falls under 'Mid-Cap' category with current market capitalization of 2.21 B. Market capitalization usually refers to the total value of a company's stock within the entire market. To calculate Immunitybio's market, we take the total number of its shares issued and multiply it by Immunitybio's current market price. To manage market risk and economic uncertainty, many investors today build portfolios that are diversified across equities with different market capitalizations. However, as a general rule, conservative investors tend to hold large-cap stocks, and these looking for more risk prefer small-cap and mid-cap equities.

Immunitybio Profitablity

Immunitybio's profitability indicators refer to fundamental financial ratios that showcase Immunitybio's ability to generate income relative to its revenue or operating costs. If, let's say, Immunitybio is currently losing money, the management's focus should be on how to reverse that trend. However, when revenue exceeds expenses, Immunitybio's executives or investors may be in less hurry to break that information down - which is where profitability analysis comes into play. Gaining a greater understanding of Immunitybio's profitability requires more research than a typical breakdown of Immunitybio's financial statements. By doing a profitability analysis, companies can identify areas needing attention, and investors can make a profitable trade.
Last ReportedProjected for 2022
Return on Average Assets(0.59) (0.64) 
Return on Average Equity(1.10) (1.13) 
Return on Invested Capital(0.45) (0.46) 
Return on Sales(748.68) (807.78) 

Management Efficiency

The entity has return on total asset (ROA) of (80.33) % which means that it has lost $80.33 on every $100 spent on asset. This is way below average. Immunitybio management efficiency ratios could be used to measure how well immunitybio manages its routine affairs as well as how well it operates its assets and liabilities. Return on Average Assets is likely to drop to -0.64 in 2022. Return on Average Equity is likely to drop to -1.13 in 2022. Immunitybio Current Assets are fairly stable at the moment as compared to the past year. Immunitybio reported Current Assets of 128.47 Million in 2021. Goodwill and Intangible Assets is likely to rise to about 1.8 M in 2022, whereas Total Assets are likely to drop slightly above 245.7 M in 2022.
Last ReportedProjected for 2022
Book Value per Share(1.04) (1.07) 
Enterprise Value over EBIT(14.40) (14.78) 
Enterprise Value over EBITDA(16.21) (16.64) 
Price to Book Value(10.87) (11.16) 
Tangible Assets Book Value per Share 1.91  2.41 
Enterprise Value1.7 B1.8 B
Tangible Asset Value252.9 M243.5 M

Technical Drivers

As of the 25th of January, Immunitybio retains the market risk adjusted performance of 15.19, and Risk Adjusted Performance of (0.046398). Immunitybio technical analysis makes it possible for you to employ historical prices and volume momentum with the intention to determine a pattern that calculates the direction of the firm's future prices. Simply put, you can use this information to find out if the firm will indeed mirror its model of historical price patterns, or the prices will eventually revert. We were able to interpolate data for nineteen technical drivers for Immunitybio, which can be compared to its competitors. Please check out Immunitybio coefficient of variation, maximum drawdown, as well as the relationship between the Maximum Drawdown and skewness to decide if Immunitybio is priced fairly, providing market reflects its last-minute price of 5.55 per share. Given that Immunitybio has jensen alpha of (0.45), we strongly advise you to confirm Immunitybio's regular market performance to make sure the company can sustain itself at a future point.

Immunitybio Price Movement Analysis

The output start index for this execution was twenty-three with a total number of output elements of thirty-eight. The Bollinger Bands is very popular indicator that was developed by John Bollinger. It consist of three lines. Immunitybio middle band is a simple moving average of its typical price. The upper and lower bands are (N) standard deviations above and below the middle band. The bands widen and narrow when the volatility of the price is higher or lower, respectively. The upper and lower bands can also be interpreted as price targets for Immunitybio. When the price bounces off of the lower band and crosses the middle band, then the upper band becomes the price target. View also all equity analysis or get more info about bollinger bands overlap studies indicator.

Immunitybio Insider Trading Activities

Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific Immunitybio insiders, such as employees or executives, is commonly permitted as long as it does not rely on Immunitybio's material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases Immunitybio insiders are required to file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.

Immunitybio Technical and Predictive Indicators

Immunitybio Forecast Models

Immunitybio time-series forecasting models is one of many Immunitybio's stock analysis techniquest aimed to predict future share value based on previously observed values. Time-series forecasting models ae widely used for non-stationary data. Non-stationary data are called the data whose statistical properties e.g. the mean and standard deviation are not constant over time but instead, these metrics vary over time. These non-stationary Immunitybio's historical data is usually called time-series. Some empirical experimentation suggests that the statistical forecasting models outperform the models based exclusively on fundamental analysis to predict the direction of the stock market movement and maximize returns from investment trading.

About Immunitybio Stock Analysis

Stock analysis is the technique used by a trader or investor to examine and evaluate how Immunitybio stock is reacting to, or reflecting on a current stock market direction and economic conditions. It can be used to make informed decisions about market timing, and when buying or selling Immunitybio shares will generate the highest return on investment. We also built our stock analysis module to help investors to gain an insight into the world economy as a whole, the stock market, thematic ideas, a specific sector, or an individual stock such as Immunitybio. By using and applying Immunitybio Stock analysis, traders can create a robust methodology for identifying Immunitybio entry and exit points for their positions.
Last ReportedProjected for 2022
EBITDA Margin(7.97) (8.60) 
Gross Margin 0.90  0.89 
Profit Margin(8.68) (9.37) 
ImmunityBio, Inc., a clinical-stage immunotherapy company, develops cell and immune therapies to treat cancers and infectious diseases. The company was founded in 2014 and is based in San Diego, California. Immunitybio operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 538 people.

Current Immunitybio Analysis - Recommendations

We track the performance of the top 100 financial experts across various large and mid-size financial boutiques. Immunitybio analyst recommendations are determined by taking all analyst recommendations and averaging them as Strong Buy, Buy, Hold, Strong Sell or Sell. There is no one specific way to measure analysis performance other than comparing it to the past results via a very sophisticated attribution analysis. Immunitybio analyst consensus and target price projections should be used in combination with other traditional techniques such as stock price forecasting, technical analysis, earnings estimate, and various momentum models.
Target PriceAdvice# of Analysts
20.0Strong Buy1Odds
Immunitybio current and past analyst recommendations published by a number of research institutions as well as average analyst consensus.
Most Immunitybio analysts issue ratings four times a year, at intervals of three months. Ratings are usually accompanied by a target price to helps potential investors understand Immunitybio stock's fair price compared to its market value. Analysts arrive at stock ratings after researching public financial statements of Immunitybio, talking to its executives and customers, or listening to Immunitybio conference calls.
Immunitybio Analyst Advice Details

Immunitybio Stock Analysis Indicators

Immunitybio stock analysis indicators help investors evaluate how Immunitybio stock reacts to ongoing and evolving market conditions. The investors can use it to make informed decisions about market timing and determine when trading Immunitybio shares will generate the highest return on investment. By understating and applying Immunitybio stock analysis, traders can identify Immunitybio position entry and exit signals to maximize returns.
Quick Ratio1.25
Fifty Two Week Low5.06
Revenue Growth-56.30%
Shares Short Prior Month9.1M
Average Daily Volume Last 10 Day1.66M
Average Daily Volume In Three Month1.61M
Shares Percent Shares Out2.62%
Gross Margins100.00%
Short Percent Of Float12.77%
Forward Price Earnings-6.31
Float Shares94.62M
Fifty Two Week High45.42
Enterprise Value To Ebitda-13.52
Fifty Day Average6.39
Two Hundred Day Average11.01
Enterprise Value To Revenue1,890.96
Please see Risk vs Return Analysis. Note that the Immunitybio information on this page should be used as a complementary analysis to other Immunitybio's statistical models used to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try Alpha Finder module to use alpha and beta coefficients to find investment opportunities after accounting for the risk.

Complementary Tools for Immunitybio Stock analysis

When running Immunitybio price analysis, check to measure Immunitybio's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Immunitybio is operating at the current time. Most of Immunitybio's value examination focuses on studying past and present price action to predict the probability of Immunitybio's future price movements. You can analyze the entity against its peers and financial market as a whole to determine factors that move Immunitybio's price. Additionally, you may evaluate how the addition of Immunitybio to your portfolios can decrease your overall portfolio volatility.
Technical Analysis
Check basic technical indicators and analysis based on most latest market data
Go
Aroon Oscillator
Analyze current equity momentum using Aroon Oscillator and other momentum ratios
Go
Portfolio Rebalancing
Analyze risk-adjusted returns against different time horizons to find asset-allocation targets
Go
Pattern Recognition
Use different Pattern Recognition models to time the market across multiple global exchanges
Go
Equity Analysis
Research over 250,000 global equities including funds, stocks and ETFs to find investment opportunities
Go
Portfolio Volatility
Check portfolio volatility and analyze historical return density to properly model market risk
Go
Premium Stories
Follow Macroaxis premium stories from verified contributors across different equity types, categories and coverage scope
Go
Fundamental Analysis
View fundamental data based on most recent published financial statements
Go
Idea Optimizer
Use advanced portfolio builder with pre-computed micro ideas to build optimal portfolio
Go
Commodity Channel Index
Use Commodity Channel Index to analyze current equity momentum
Go
Insider Screener
Find insiders across different sectors to evaluate their impact on performance
Go
Portfolio Optimization
Compute new portfolio that will generate highest expected return given your specified tolerance for risk
Go
Is Immunitybio's industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Immunitybio. If investors know Immunitybio will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Immunitybio listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
The market value of Immunitybio is measured differently than its book value, which is the value of Immunitybio that is recorded on the company's balance sheet. Investors also form their own opinion of Immunitybio's value that differs from its market value or its book value, called intrinsic value, which is Immunitybio's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Immunitybio's market value can be influenced by many factors that don't directly affect Immunitybio's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Immunitybio's value and its price as these two are different measures arrived at by different means. Investors typically determine Immunitybio value by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Immunitybio's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.